Skip to content

Odyssey Health, Inc.: 10-Q filed 2024-06-14

What Odyssey Health, Inc. reported in its quarterly report filed 2024-06-14 (fiscal Q3 2024): 29 published measures, 91 facts as tagged in accession 0001683168-24-004251.

This filing

Form
10-Q (quarterly report)
Filed
2024-06-14
Fiscal period
fiscal Q3 2024
Accession
0001683168-24-004251 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Odyssey Health, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-04-3013,575,877USD
At 2023-07-31455,793USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-04-307,879,554USD
At 2024-01-318,670,412USD
At 2023-10-31-6,218,273USD
At 2023-07-31-6,155,929USD
At 2023-04-30-5,820,231USD
At 2023-01-31-5,366,781USD
At 2022-10-31-5,383,797USD
At 2022-07-31-4,643,617USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-04-3066,014USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-02-01 to 2024-04-30-842,341USD90
2023-08-01 to 2024-04-3011,897,190USD274
2023-11-01 to 2024-01-3113,277,566USD92
2023-08-01 to 2023-10-31-538,035USD92
2023-02-01 to 2023-04-30-1,284,104USD89
2022-08-01 to 2023-04-30-5,105,412USD273
2022-11-01 to 2023-01-31-1,671,728USD92
2022-08-01 to 2022-10-31-2,149,580USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-08-01 to 2024-04-30-1,151,575USD274
2022-08-01 to 2023-04-30-1,354,850USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-08-01 to 2024-04-30180,724USD274
2022-08-01 to 2023-04-301,291,588USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-08-01 to 2024-04-301,000,000USD274
2022-08-01 to 2023-04-30-8,038USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-04-30-48,263,640USD
At 2023-07-31-60,097,375USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-02-01 to 2024-04-30103,789,222shares90
2023-08-01 to 2024-04-3094,496,866shares274
2023-02-01 to 2023-04-3083,162,747shares89
2022-08-01 to 2023-04-3081,835,188shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-02-01 to 2024-04-30103,789,222shares90
2023-08-01 to 2024-04-30113,895,608shares274
2023-02-01 to 2023-04-3083,162,747shares89
2022-08-01 to 2023-04-3081,835,188shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-02-01 to 2024-04-30-0.01USD/shares90
2023-08-01 to 2024-04-300.13USD/shares274
2023-02-01 to 2023-04-30-0.02USD/shares89
2022-08-01 to 2023-04-30-0.06USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-02-01 to 2024-04-30-0.01USD/shares90
2023-08-01 to 2024-04-300.11USD/shares274
2023-02-01 to 2023-04-30-0.02USD/shares89
2022-08-01 to 2023-04-30-0.06USD/shares273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-08-01 to 2024-04-301,051,602USD274
2022-08-01 to 2023-04-302,427,500USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-02-01 to 2024-04-30-372,371USD90
2023-08-01 to 2024-04-30-2,377,043USD274
2023-02-01 to 2023-04-30-1,094,610USD89
2022-08-01 to 2023-04-30-4,658,907USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-04-30153,403USD
At 2023-07-31405,888USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-02-01 to 2024-04-30102,227USD90
2023-08-01 to 2024-04-30434,689USD274
2023-02-01 to 2023-04-30189,415USD89
2022-08-01 to 2023-04-30454,907USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-04-305,696,323USD
At 2023-07-316,611,722USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-04-301,296,567USD
At 2023-07-311,797,656USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-04-300USD
At 2023-07-3149,905USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-04-3096,359,763shares
At 2023-07-3179,067,879shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-04-3066,014USD
At 2023-07-3136,865USD
At 2023-04-301,234USD
At 2022-07-3172,534USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-04-3056,046,834USD
At 2023-07-3153,862,378USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-04-3064,764USD
At 2023-07-3192,457USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-02-01 to 2024-04-30-842,341USD90
2023-08-01 to 2024-04-3011,833,735USD274
2023-02-01 to 2023-04-30-1,284,104USD89
2022-08-01 to 2023-04-30-5,105,412USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-02-01 to 2024-04-30320,888USD90
2023-08-01 to 2024-04-301,259,606USD274
2023-02-01 to 2023-04-30505,606USD89
2022-08-01 to 2023-04-302,102,132USD273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2024-02-01 to 2024-04-300USD90
2023-08-01 to 2024-04-301,538USD274
2023-02-01 to 2023-04-301,022USD89
2022-08-01 to 2023-04-302,529USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-02-01 to 2024-04-30186USD90
2023-08-01 to 2024-04-309,144USD274
2023-02-01 to 2023-04-30-79USD89
2022-08-01 to 2023-04-308,402USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-08-01 to 2024-04-3036,319USD274
2022-08-01 to 2023-04-300USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-08-01 to 2024-04-30-175,416USD274
2022-08-01 to 2023-04-30364,111USD273

Inspect the source

Entity
Odyssey Health, Inc. / CIK 0001626644
Captured
2026-09-19T11:19:48.570Z
SEC response SHA-256
1be33e1ca79fd1e1d5399b519a2ef141b4c1191380216b92c135e07a22902f7b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001626644.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))